Drug intelligence / Profile preview

ketamine hydrochloride + magnesium sulphate + sodium chloride

Development stage: Approved
Lead developer: Silo Pharma
Modality: Small Molecules
Administration: Intravenous

Overview

A combination medication consisting of ketamine hydrochloride, magnesium sulphate, and sodium chloride. This combination leverages the synergistic effects between ketamine (an NMDA receptor antagonist) and magnesium sulfate (which enhances NMDA receptor blockade) for improved analgesia and anesthesia, with sodium chloride serving as a diluent to create an isotonic solution. The combination is used primarily for anesthesia, pain management, and as part of opioid-free anesthesia protocols.

Targets

NMDAR (Glutamate receptor ionotropic, NMDA)

Beyond the preview

Go deeper on ketamine hydrochloride + magnesium sulphate + sodium chloride.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on ketamine hydrochloride + magnesium sulphate + sodium chloride.

Explore the full profile